BEIJING
InnoCare Pharma (HKEX: 09969), a clinical-stage biopharmaceutical company, announced today that the company will present latest clinical data of its BTK inhibitor Orelabrutinib at the 62nd American Society of Hematology (ASH) Annual Meeting on December 5-8, 2020, which will be held online. The study in Patients with Relapsed or Refractory Mantle Cell Lymphoma, led by Dr. Jun Zhu, and the study in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Cell Leukemia, led by Dr. Jianyong Li, will be presented in three posters. This is the second consecutive year for InnoCare to present Orelabrutinib data at ASH.
Poster Presentation 1：
Title：Pooled Analysis of Safety Data from Clinical Trials of Orelabrutinib Monotherapy in Hematologic Malignancies
Abstract Number：1140
Session Name: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster I
Session Date: Saturday, December 5, 2020
Presentation Time: 7:00 AM-3:30 PM
Location: Poster Hall (Virtual Meeting)
Presenter: Yuqin Song, M.D., Ph.D.
Abstract website: https://ash.confex.com/ash/2020/webprogram/Paper140172.html
Poster Presentation 2：
Title：Long-Term Safety and Efficacy of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter, Open-Label, Phase II Study
Abstract Number：2048
Session Name: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster II
Session Date: Sunday, December 6, 2020
Presentation Time: 7:00 AM-3:30 PM
Location: Poster Hall (Virtual Meeting)
Presenter: Yuqin Song, M.D., Ph.D.
Abstract website: https://ash.confex.com/ash/2020/webprogram/Paper141781.html
Poster Presentation 3：
Title：Updated Results from the Phase II Study of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Cell Leukemia
Abstract Number：1320
Session Name: 642. CLL: Therapy, excluding Transplantation: Poster I
Session Date: Saturday, December 5, 2020
Presentation Time: 7:00 AM-3:30 PM
Location: Poster Hall (Virtual Meeting)
Presenter: Wei Xu, M.D.
Abstract website: https://ash.confex.com/ash/2020/webprogram/Paper134531.html
InnoCare will release detailed Orelabrutinib clinical data during ASH meetings.
About Orelabrutinib
Orelabrutinib is a selective BTK inhibitor for the treatment of cancers and autoimmune diseases, which has been supported by the national special project for the development of major new drugs. Currently, multi-center, multi-indication clinical trials are underway in the US and China with orelabrutinib as monotherapy or in combination therapies. Current clinical data have demonstrated orelabrutinib’s robust efficacy and safety profile. Orelabrutinib’s two indications have been included in priority review by the NMPA.
About InnoCare Pharma
InnoCare Pharma is a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of first-in-class and/or best-in-class drugs for the treatment of cancer and autoimmune diseases. We strategically focus on lymphoma, solid tumors, and autoimmune disease with high unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, New Jersey, and Boston.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201105005636/en/
CONTACT
Media
Chunhua Lu
86-10-66609879
chunhua.lu@innocarepharma.com
Investor Relations
86-10-66609999
ir@innocarepharma.com
